Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving physiologic swallowing and venting mechanisms, MSA offers a less disruptive alternative to traditional antireflux surgery.
Introduction:
Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving physiologic swallowing and venting mechanisms, MSA offers a less disruptive alternative to traditional antireflux surgery. Although short- and intermediate-term outcomes have been favorable, robust long-term data have been limited.
Problem Statement:
For any implantable antireflux device, long-term durability, symptom control, dependence on acid-suppressive medications, and device-related complications are critical considerations. Questions remain regarding the sustainability of reflux control beyond five years and the frequency of device removal or adverse events over time.
Summary:
This FDA post-approval study provides important long-term evidence on the effectiveness and safety of magnetic sphincter augmentation in patients with GERD. At more than five years of follow-up, most patients experienced sustained and clinically meaningful improvement in reflux-related quality of life, with the vast majority remaining free from daily proton pump inhibitor use. Objective testing confirmed durable reflux control, demonstrating persistent normalization of esophageal acid exposure in a substantial proportion of patients. A notable advantage of MSA was preservation of physiologic functions such as belching and vomiting, which are often impaired after conventional fundoplication. Dysphagia remained uncommon and generally manageable. Device-related complications were infrequent, with erosion occurring rarely. However, approximately one in eight patients required device explantation during long-term follow-up. Reassuringly, most patients who underwent device removal achieved symptom resolution through explantation alone, conversion to fundoplication, or device replacement. These findings demonstrate that MSA provides durable long-term control of GERD symptoms and reduces dependence on acid-suppressive medication while maintaining favorable functional outcomes. Although a minority of patients may ultimately require device removal, the overall long-term safety and efficacy profile supports MSA as an established surgical option for appropriately selected patients with chronic GERD.
Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...
Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...
Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...
Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...
Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...
Introduction Helicobacter pylori Infection remains a major global cause of peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Rising antimicrobial resistance, particularly to clarithromycin, has progressively reduced eradication success with conventional triple therapy....
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.